Core Points - Aorite (605116.SH) announced a share buyback program, having repurchased a total of 2.3502 million shares as of November 30, 2025, which represents 0.58% of the company's total share capital [1] - The highest price paid for the repurchased shares was 22.59 CNY per share, while the lowest price was 18.83 CNY per share [1] - The total amount spent on the share buyback was approximately 48.9994 million CNY, excluding transaction fees [1]

| 证券代码：605116 | 证券简称：奥锐特 | 公告编号：2025-086 | | --- | --- | --- | | 债券代码：111021 | 债券简称：奥锐转债 | | 奥锐特药业股份有限公司 关于以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2025/1/22 | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 2025 年 1 月 | 21 日~2026 | 年 | 1 | 月 | 20 日 | | 预计回购金额 | 6,000万元~12,000万元 | | | | | | | 回购用途 | □减少注册资本 □用于员工持股计划或股权激励 | | | | | | | | √用于转换公司可转债 | | | | | | | | □为维护公司价值及股东权益 | | | | | | | 累计已回购股数 | 2,350,238股 | | | | | ...

Group 1 - The company’s executive Zhao Zhenping held 250,000 shares before the reduction plan, accounting for 0.06% of the total share capital, with shares obtained through equity incentives [1] - Zhao Zhenping planned to reduce his holdings by up to 62,500 shares, representing no more than 0.02% of the total shares, due to personal financial needs, with the reduction period set for three months after the announcement [1] - As of the announcement date, Zhao Zhenping successfully reduced his holdings by 62,500 shares, completing the reduction plan [1] Group 2 - The reduction plan was fully implemented, and the actual reduction matched the previously disclosed plan [2] - The reduction was completed within the specified time frame, confirming that the plan was executed as intended [2] - There was no early termination of the reduction plan [2]

Core Viewpoint - Aorete announced the completion of a stock reduction plan by executive Zhao Zhenping, indicating a strategic move in the company's stock management [2] Group 1: Company Actions - Aorete received a notification from executive Zhao Zhenping regarding the completion of a securities trading plan on November 25, 2025 [2] - Zhao Zhenping reduced his holdings by 62,500 shares, which represents 0.02% of the company's total share capital [2] - The stock reduction plan has been fully implemented as of the announcement date [2]

| 证券代码：605116 | 证券简称：奥锐特 | 公告编号：2025-085 | | --- | --- | --- | | 债券代码：111021 | 债券简称：奥锐转债 | | 奥锐特药业股份有限公司 高管减持股份结果公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 减持计划的实施结果情况 公司于 2025 年 8 月 5 日披露了《奥锐特药业股份有限公司关于部分高管减 持股份计划公告》（公告编号：2025-054），赵珍平先生因个人资金需求，拟通过 集中竞价方式减持公司股份数量不超过 62,500 股，减持比例为不超过公司股份 总数的 0.02%，减持期间为减持股份计划公告发布之日起 15 个交易日后的 3 个 月内，若减持期间公司有派发红利、送红股、转增股本、增发新股或配股等股份 变动事项，拟减持数量将进行相应调整。 公司于 2025 年 11 月 25 日收到高管赵珍平先生《关于证券交易计划实施完 成的告知函》。截至本公告披露日，赵珍平先生通过集中竞价方式减持公司股票 62,500 股，占公司总股本 ...

Core Viewpoint - The company announced that executive Zhao Zhenping has reduced his shareholding by selling 62,500 shares, which represents 0.02% of the total share capital, due to personal financial needs [1] Summary by Relevant Sections - **Share Reduction Details** - The share reduction took place from November 4, 2025, to November 25, 2025 [1] - The selling price ranged from 22.00 to 23.50 yuan per share [1] - The total amount raised from the share reduction was 1.4163 million yuan [1] - **Compliance with Previous Plans** - The actual reduction aligns with the previously disclosed reduction plan, confirming that the plan has been fully executed [1]

Core Viewpoint - Aorite Pharmaceutical Co., Ltd. has received approval from the National Medical Products Administration for the registration of a combined packaging of estradiol tablets and estradiol/dydrogesterone tablets, which is expected to enhance the company's market competitiveness and positively impact its operating performance [1][5][6]. Group 1: Drug Registration Information - The drug is named estradiol tablets/estradiol/dydrogesterone tablets combined packaging, with a registration number of 2025S03486 [1]. - The formulation includes estradiol 2mg and dydrogesterone 10mg [1]. - The drug is classified as a Class 4 chemical drug and is produced by Aorite's subsidiary, Yangzhou Aorite Pharmaceutical Co., Ltd. [1][2]. Group 2: Market Situation - The drug is indicated for the treatment of menopausal syndrome caused by natural or surgical menopause [2]. - The drug was originally developed by Abbott B.V. and was approved for domestic sale in 2015 under the brand name "Fentam." [3]. - As of now, there are two companies, Abbott and Yangzhou Aorite, that have passed the consistency evaluation for this drug in China [3]. Group 3: Financial Investment - As of October 31, 2025, the company has invested approximately 12.64 million RMB in the research and development of this drug [4]. - The hospital sales revenue for "Fentam" is projected to be 564 million RMB in 2024 [4]. Group 4: Impact on Company - The approval of the drug registration is expected to enhance the company's competitiveness in the pharmaceutical market [5]. - The new product's market entry is anticipated to have a positive effect on the company's financial performance [5].

Group 1 - The core point of the article is that Aorite has received a drug registration certificate for a combined packaging of estradiol tablets and estradiol/dydrogesterone tablets from the National Medical Products Administration [2] Group 2 - Aorite's wholly-owned subsidiary, Yangzhou Aorite Pharmaceutical Co., Ltd., is the entity that received the approval [2]

Core Viewpoint - Aorite (605116.SH) has received approval from the National Medical Products Administration for the registration of a combined packaging of estradiol tablets and dydrogesterone tablets, which is expected to enhance the company's market competitiveness and positively impact its operating performance [1] Group 1 - Aorite's wholly-owned subsidiary, Yangzhou Aorite, has been granted a drug registration certificate for the combined packaging of estradiol tablets and dydrogesterone tablets [1] - The drug, developed by Abbott B.V., is intended for the treatment of menopausal syndrome caused by natural or surgical menopause [1] - The combined packaging was initially approved for import in 2015 under the brand name "Feminine" [1] Group 2 - The new drug registration is classified under the new registration method for chemical drugs, which is expected to improve the company's competitive position in the pharmaceutical market [1] - The approval of this product for domestic sales is anticipated to have a positive effect on the company's financial performance [1]

Core Viewpoint - The company, Aorite (605116.SH), has received approval from the National Medical Products Administration for a combined packaging of estradiol tablets and estradiol-dydrogesterone tablets, which is expected to enhance its market competitiveness and positively impact its financial performance [1]. Group 1 - Aorite's wholly-owned subsidiary, Yangzhou Aorite Pharmaceutical Co., Ltd., has obtained a drug registration certificate for the combined packaging of estradiol tablets and estradiol-dydrogesterone tablets [1]. - The approved product is intended for the treatment of perimenopausal syndrome caused by natural or surgical menopause [1]. - The registration of the product under the new classification method for chemical drugs is expected to improve the company's market position in this therapeutic area [1].